Ignore the Noise—Samsara Stock Is Still a Strong Buy

Written by Sam Quirke

Samsara Inc. (NYSE: IOT) is no stranger to being misunderstood by the market. Back in March, we highlighted how the stock’s dip was actually a solid buying opportunity, and it went on to rally 45%. Now, history might be repeating. Shares have pulled back following last week’s Q1 report, but a closer look shows plenty of reasons to stay bullish.

In fact, the latest quarterly numbers not only beat expectations but also revealed accelerating growth, expanding margins, and a strengthening pipeline. With analysts reiterating bullish ratings and even raising price targets, investors on the sidelines should be getting excited about this tech giant’s prospects.

Samsara’s Q1 Revenue Surges Over 30% Year-Over-Year

Starting with the fundamentals, Samsara delivered $366.9 million in revenue for the first quarter, which was up more than 30% on the year. Like with its EPS print, analyst expectations were beaten pretty much across the board, something Samsara has a habit of doing.

CEO Sanjit Biswas described the results as “a strong first quarter of the new fiscal year” and highlighted the company’s ability to deliver clear, fast ROI through its AI-powered platform. He also called out a record pipeline and continued efficiency gains, both of which should help drive further margin expansion in the months ahead.

For all the bright spots, though, it’s clear the market was spooked by the tariff-driven delays in deal closures and updated forward guidance, which seems to have underwhelmed. Still, this is a company that’s close to firing on all cylinders, and the post-earnings dip is compelling for those with a long-term horizon.

Analysts Are Doubling Down on Samsara

Backing up this theory is the fact that the post-earnings dip wasn’t mirrored one bit in the analyst community. If anything, the report only strengthened conviction among the bulls.

Wells Fargo, for example, reiterated its Overweight rating on Samsara and increased its price target to $50. BMO Capital Markets echoed the move, lifting its target to $54. From where the stock was trading early Thursday, this implies a potential upside of more than 35%.

Both firms cited strong ARR growth, resilient demand trends, and Samsara’s growing list of major partnerships. These integrations are expected to streamline electric fleet management and deepen Samsara’s reach into cloud-based vehicle operations.

Another bullish catalyst is the company’s expanding presence in under-digitized sectors like public infrastructure and construction. CEO Biswas pointed to new product features that use gamification to improve safety outcomes and enhance employee engagement, factors that directly translate into higher retention and usage across large enterprise customers.

Technicals Still Suggest a Bounce Is Likely

From a technical standpoint, Samsara’s pullback is also starting to look like an opportunity rather than a red flag. The stock’s relative strength index (RSI) has now dipped below the 40 mark and is verging on extremely oversold territory. When viewed in the context of record revenue and strong earnings, it’s hard to see this as anything other than a red-hot bargain.

That said, it will be critical for the stock to hold above the $40 mark in the sessions ahead, as any close below that would be a new post-earnings low. Wall Street could interpret that as a signal that the bears are in control, for the short term at least, and they may take on a “wait and see” approach before backing up the truck.

But don’t forget, this isn’t the first time Samsara has sold off on good news. The stock did the same back in March, only to roar back in the following weeks. With it having since posted another quarter of record revenue, topping analysts’ expectations once again, and getting boosted price targets, which now sit well above $50, the stage could be set for another similar move.

READ THIS STORY ONLINE

Gold Breaks Records: 4 Stocks Poised to Ride the Wave (Ad)

We’ve put together Free Report revealing 4 gold stocks with breakout potential as gold prices climb higher. These aren’t just safe havens—they’re strategic plays built for growth.

CLICK HERE TO DOWNLOAD TOP 4 GOLD STOCKS REPORT

3 Stocks Set to Double—And There’s Still Time to Buy

Written by Nathan Reiff

Chasing momentum trends is risky business for investors. By the time many retail investors are aware of building momentum for a particular stock, it may be too late to fully capitalize on future gains. Worse yet, investors may buy a company too late in the hype cycle and wind up holding shares that are declining in value.

While timing the market is inherently challenging, investors who turn to stocks with strong analyst sentiment, lofty price targets, and compelling operations are better positioned to capture gains from a momentum play.

Below are three companies with consensus price targets at least twice the current price point. All might be worth watching for their future growth potential, although investors should also consider the risks inherent to a momentum investing strategy.

Leading Battery Developer Has Momentum and Short Squeeze Potential

Enovix Corp. (NASDAQ: ENVX) makes lithium-ion batteries for use in electric vehicles, grid storage, and consumer electronics. The company’s batteries have risen in popularity due to their comparably high energy density, charge rates, and discharge capabilities over rival products.

Short interest in ENVX shares stands at nearly 46 million shares, or more than 28% of float, and the stock’s 16% rise in the last month puts those short sellers at risk of a squeeze.

Anticipated revenue growth for Enovix could also drive a short squeeze. As the firm builds up its manufacturing capacity, orders and defense bookings have also increased. Enovix is also developing a custom smartphone cell with significant demand potential.

The company is also somewhat insulated from concerns surrounding the evolving tariff landscape because it builds its batteries in Asia, and many of its customers are also in Asia, bypassing the need for transit through the United States.

Analysts are largely bullish on Enovix shares, as eight have rated the stock a Buy compared to three Holds. Despite the recent rally, analysts view significant upside potential for the company as well.

The consensus price target of $17.27 would suggest that the price of ENVX could more than double going forward.

Analysts Bullish on AnterixAccelerator and Utility Broadband Expansion

Communications firm Anterix Inc. (NASDAQ: ATEX) offers private wireless broadband service, primarily to utility and critical infrastructure customers. The company reached a 52-week low in early June 2025, but analysts expect its AnterixAccelerator project to drive business from utilities firms nationwide.

This could boost revenue, with estimates of 48% revenue improvement for the current year in some cases.

AnterixAccelerator is an initiative partnering with major wireless service providers to drive adoption of 900 MHz private wireless networks by utilities firms. As of the initiative’s launch in April, Anterix reported 15 utilities companies participating; this figure is likely to expand as the project’s success grows, given the goal of integrating intelligence across a national utilities grid.

Both analysts rating ATEX shares in recent months have assigned it a Buy, and based on consensus price estimates, the stock enjoys more than 145% upside potential.

Connected Car Business Drives Xperi to Profitability, Suggests Key Focus Going Forward

Xperi Inc. (NASDAQ: XPER) provides pay-TV services, UX solutions, and more, catering to service providers. Although revenue declined modestly year-over-year (YOY) for the first quarter of the year amid a challenging external environment, Xperi swung to non-GAAP earnings per share (EPS) of 16 cents from a loss last year. The company’s profitability has improved significantly, largely thanks to its connected car business and its 37% YOY revenue improvement.

Xperi’s connected car business appears to be in a position to continue growing. By the end of 2025, the company aims to expand its AutoStage footprint to more than 13 million vehicles and add monetization in many cases, increasing its DT.

Suppose the company can remain focused on building its customer base, improving efficiency, and managing its debt and cash flow successfully. In that case, shares of XPER are likely to benefit. Analysts see shares climbing by almost 136% over current levels, and all three ratings of the stock call for a Buy.

READ THIS STORY ONLINE

3 Under-$10 Stocks That Could Skyrocket (Ad)

Often, investors will overlook stocks just because they’re cheap.

It’s a common thought that a cheap price tag means that something must be wrong with the company.

But this couldn’t be further from the case in many instances.

GET YOUR FREE LOOK AT THESE THREE COMPANIES RIGHT HERE.

Analysts Can’t Get Enough of These Little-Known Biopharma Stocks

Written by Nathan ReiffThe biopharmaceuticals industry is both exciting and risky for investors. Many leading growth stocks in the U.S. market are found in this sector, due to the significant rallies that biopharmaceutical companies experience when a key positive trial result is announced or an important drug receives government approval.

On the other hand, a host of biopharma firms face near-constant threats of collapse, given that most of these companies lack sufficient revenue to sustain operations for long unless a breakthrough occurs.

Investors outside the space may wonder how to balance their own risk tolerance with the risk/reward profile of many biopharma companies. Although it’s not a guarantee of success, one approach involves deferring to Wall Street analysts who are experts in the healthcare sector.

By identifying companies that analysts love, particularly those that have yet to reach mainstream recognition, investors may be able to target high-potential investments before those companies see breakout success.

Notable Safety Performance for a Flagship Protein Degradation Candidate

Kymera Therapeutics Inc. (NASDAQ: KYMR) develops small-molecule therapeutics to selectively degrade disease-causing proteins. In early June, the company announced positive Phase 1 trial results for KT-621, its flagship oral STAT6 degrader medicine. The drug candidate is likely to undergo continued trials for moderate to severe atopic dermatitis this year.

The results for KT-621 are not only beneficial for Kymera because they bring the drug one step closer to commercialization, but they also provide some investors with evidence of the efficacy and safety of Kymera’s broader therapeutic platform.

By attempting to utilize the body’s natural protein degradation system for clinical treatments, Kymera stands apart from many other biopharma firms. Strong safety results from this trial are promising for Kymera’s future drug candidates as well.

Kymera also benefits from a robust pipeline of other drugs in development and a partnership with AI-powered biopharma developer Sanofi. The company has substantial cash reserves that are expected to sustain operations through 2028, buying it time to achieve critical drug development milestones.

Given all of these favorable factors, it’s no surprise that 17 out of 18 analysts have rated KYMR shares a Buy, assigning it a consensus price target more than 22% higher than current levels.

Promising Results and Analyst Optimism Despite Some Risks

Clinical-stage biopharma firm Vera Therapeutics Inc. (NASDAQ: VERA) makes treatments for immunological diseases. One of its leading candidates is atacicept, which recently completed a Phase 3 trial for the chronic kidney disease immunoglobulin A nephropathy (IgAN).

The results were positive, including in the area of safety, putting Vera on the path to seeking FDA approval for a Biologics License Application by later this year and a commercial launch sometime in 2026.

Additional results remain pending for atacicept, which could help further support its commercialization, but that also introduces a bit of uncertainty for investors who are keen on gaining exposure to Vera on the promise of this new drug.

Further, other drug developers are also pursuing treatments for IgAN, potentially limiting Vera’s ability to capitalize on atacicept if and when it does reach commercialization.

Despite these risks, nine out of 10 analysts believe Vera is a Buy. Though some analysts have lowered their price targets for VERA shares in recent months, the consensus price target still suggests the stock could nearly triple over its current price.

Lead Candidate Shines in Trials for Epilepsy, Potential in Bipolar Mania Too

Rapport Therapeutics Inc. (NASDAQ: RAPP) discovers and develops medicines for the treatment of neurological and psychiatric disorders. With a cash supply that should support operations for another four years, roughly, the company has ample time to continue to progress its candidate RAP-219 toward commercialization.

RAP-219 aims to treat refractory focal epilepsy and saw positive trial data early in 2025. Rapport expects results from the Phase 2a trial in the third quarter of the year.

Additionally, RAP-219 is undergoing clinical trials for the treatment of bipolar mania, with a new trial set to begin later this year as well.

Rapport doesn’t have the same degree of analyst coverage as the companies above, but all four analysts reviewing the firm agree that it is a Buy.

With nearly 168% upside potential, confidence in the company’s ability to successfully navigate RAP-219 through the trial process is high.

READ THIS STORY ONLINE

5 Stocks That Could Double Your Investment in 2025 (Ad)

5 Stocks That Could Double in 2025 🚀

Our analysts have identified five stocks with the potential to double in 2025. From a company poised to lead the crypto ETF market to an innovator in fuel cell technology for AI and data centers, these picks could be game-changers for your portfolio.

DON’T MISS THESE INSIGHTS.